

Strongbridge Biopharma Plc Announces Launch of Its Proposed Initial U.S. Public Offering

September 21, 2015 3:23 PM ET

September 21, 2015 - Dublin, Ireland and Trevese, Pa., USA – Strongbridge Biopharma plc announced today that it has commenced its initial U.S. public offering of 4,250,000 ordinary shares. In connection with this offering, Strongbridge Biopharma expects to grant to the underwriters a 30-day option to purchase up to an additional 637,500 ordinary shares. The ordinary shares are currently quoted on the NOTC, A-list in Norway under the symbol “SBBP,” and Strongbridge Biopharma has applied to list its ordinary shares on The NASDAQ Global Market under the same symbol.

BofA Merrill Lynch and Stifel are acting as joint book-running managers of the proposed offering. JMP Securities is acting as lead manager and Roth Capital Partners and Arctic Securities are acting as co-managers.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus related to the offering may be obtained from: BofA Merrill Lynch, 222 Broadway, New York, New York 10038, Attention: Prospectus Department or by emailing dg.prospectus_requests@baml.com; or Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.

About Strongbridge Biopharma

Strongbridge Biopharma’s strategic focus is to build a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. Strongbridge Biopharma’s lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing’s syndrome. COR-003 has received orphan designation from both the European Medicines Agency and the U.S. Food and Drug Administration. Strongbridge Biopharma recently expanded its rare endocrine disease franchise with the completion of transactions for two Phase 2 product candidates: COR-004, a novel second-generation antisense compound, which is in clinical development for acromegaly and designed to block the synthesis of growth hormone receptor (GHR) thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile, being investigated for the treatment of acromegaly, with potential additional applications in Cushing’s disease and neuroendocrine tumors. Strongbridge Biopharma’s intent is to independently commercialize its rare endocrine assets in key global markets.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including, without limitation, statements regarding the anticipated public offering, the size of the offering and the listing of the ordinary shares on The NASDAQ Global Market, are forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and no assurance can be given that the anticipated public offering will be consummated on the terms described above or at all. Completion of the anticipated public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Strongbridge Biopharma, including, without limitation, market conditions and the risk factors and other matters set forth in Strongbridge Biopharma’s filings with the U.S. Securities and Exchange Commission. The words “anticipate,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will,” “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements

are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. The forward-looking statements contained in this press release are made as of the date of this press release, and Strongbridge Biopharma does not assume any obligation to update any forward-looking statements except as required by applicable law.

Contacts:

Corporate and Media Relations

Elixir Health Public Relations

Lindsay Rocco

+1 862-596-1304

lrocco@elixirhealthpr.com

Investor Relations

ICR Inc.

Stephanie Carrington

+1 646-277-1282

Stephanie.Carrington@icrinc.com

USA

900 Northbrook Drive

Suite 200

Treose, PA 19053

Tel. +1 610-254-9200

Fax. +1 215-355-7389